Sanofi and MannKind strike Afrezza deal

French pharmaceutical company Sanofi and the US-based MannKind Corporation have entered into an exclusive licensing agreement to develop and commercialise MannKind’s Afrezza (insulin human), an inhalable insulin therapy for adults with types 1 and 2 diabetes.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Merchant & Gould hires 13 attorneys to open new Boston office

6 January 2026 The new recruits from a boutique Boston firm enables Merchant to expand and strengthen its tech and life sciences offering in the innovation hub.

Americas

PTAB year in review: A shifting landscape and outlook for 2026

2 January 2026 With the unprecedented changes at the PTAB in 2025, what could the year ahead hold for the agency? Lawyers from Sterne Kessler explore.

Americas

5 ways the USPTO director is changing US innovation

24 December 2025 John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.

More features

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Merchant & Gould hires 13 attorneys to open new Boston office

Novo Nordisk secures China win ahead of key patent expiration

Edwards v Meril: Inside the UPC’s landmark medtech showdown

Bird & Bird targets Nordic life sciences growth with regulatory hire

Key EU and UK regulatory changes to watch for in 2026

PTAB year in review: A shifting landscape and outlook for 2026

UPC: A review of 2025 and what to expect in 2026

Sanofi and MannKind strike Afrezza deal

More on this story

Editor's picks

Editor's picks

More features